KR20190062502A - 급성 신장 손상을 치료하는 방법 - Google Patents
급성 신장 손상을 치료하는 방법 Download PDFInfo
- Publication number
- KR20190062502A KR20190062502A KR1020197012516A KR20197012516A KR20190062502A KR 20190062502 A KR20190062502 A KR 20190062502A KR 1020197012516 A KR1020197012516 A KR 1020197012516A KR 20197012516 A KR20197012516 A KR 20197012516A KR 20190062502 A KR20190062502 A KR 20190062502A
- Authority
- KR
- South Korea
- Prior art keywords
- patient
- acute renal
- compound
- renal failure
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- CVJOHJWLCVAMCE-GOSISDBHSA-N Cc1cnc(-c2cnc(C(F)(F)F)cc2)[n]1Cc(cccc1)c1OCCC[C@H](CC(O)=O)N Chemical compound Cc1cnc(-c2cnc(C(F)(F)F)cc2)[n]1Cc(cccc1)c1OCCC[C@H](CC(O)=O)N CVJOHJWLCVAMCE-GOSISDBHSA-N 0.000 description 1
- WNDPXYAVRBQZAL-UHFFFAOYSA-N Cc1cnc(-c2cnc(C(F)(F)F)cc2)[n]1Cc1ccccc1OC Chemical compound Cc1cnc(-c2cnc(C(F)(F)F)cc2)[n]1Cc1ccccc1OC WNDPXYAVRBQZAL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| US62/404,390 | 2016-10-05 | ||
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190062502A true KR20190062502A (ko) | 2019-06-05 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197012516A Ceased KR20190062502A (ko) | 2016-10-05 | 2017-10-05 | 급성 신장 손상을 치료하는 방법 |
Country Status (33)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017062468A1 (en) | 2015-10-07 | 2017-04-13 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| JP6925367B2 (ja) * | 2016-04-13 | 2021-08-25 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
| US10927094B2 (en) * | 2016-10-05 | 2021-02-23 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
| AU2020317631B2 (en) * | 2019-07-19 | 2025-09-18 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5016922B2 (ja) * | 2003-09-19 | 2012-09-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物 |
| RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| MX2011004077A (es) * | 2008-10-17 | 2011-08-17 | Metabolex Inc | Metodos para reducir particulas de ldl densas, pequeñas. |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| WO2014138738A1 (en) * | 2013-03-08 | 2014-09-12 | Abbive Inc. | Methods of treating acute kidney injury |
| EP2981522A4 (en) * | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| EP2862574A1 (en) * | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| JP2016540759A (ja) * | 2013-12-03 | 2016-12-28 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| WO2017062468A1 (en) * | 2015-10-07 | 2017-04-13 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
-
2017
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190062502A (ko) | 급성 신장 손상을 치료하는 방법 | |
| US20240067600A1 (en) | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | |
| US11548895B2 (en) | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile | |
| JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
| CN104023723B (zh) | 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物 | |
| KR19990072616A (ko) | 심부전증치료용약학조성물 | |
| RU2468015C2 (ru) | Полиморфные формы деферасирокса (icl670a) | |
| US12049446B2 (en) | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof | |
| JP7322007B2 (ja) | インドール化合物を含むネフローゼ症候群の治療又は予防剤 | |
| JP2018515454A (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
| JP2022065014A (ja) | 重水素化イミダゾリジンジオン化合物とその用途 | |
| JP6814134B2 (ja) | 糖尿病性腎症を治療又は予防する方法 | |
| CN119241400B (zh) | 一种脒基磺酰胺衍生物及其应用 | |
| US20090105301A1 (en) | 9a-substituted azalides for the treatment of malaria | |
| HK40008682B (en) | Methods of treating acute kidney injury | |
| HK40008682A (en) | Methods of treating acute kidney injury | |
| KR20210106538A (ko) | 약학적 화합물, 이를 만드는 방법 및 의약품으로서의 용도 | |
| CN116648445A (zh) | 治疗或预防慢性肾脏病的方法 | |
| CZ182895A3 (en) | Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide per se and for treating diseases, and pharmaceutical composition based thereon | |
| JP2008156313A (ja) | アミロイド疾患の治療およびモニタリングのための薬剤 | |
| JPH05194424A (ja) | 新規なピリミジン誘導体及び該誘導体を有効成分とする医薬 | |
| WO2003050097A1 (en) | Sodium salt of benzyl thiazolidine-2,4-dione derivative and hydrate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190430 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200716 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220216 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20220830 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220216 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |